Fierce Biotech June 7, 2024
After previewing its potential acquisition agreement earlier this year, laparoscopic robotics developer Asensus Surgical has made it official: It will be bought out by Karl Storz.
The German medtech company will pay the previously agreed-upon price of 35 cents per share, or about $95 million—which Asensus described as a 67% premium over its stock value in early April, before it first announced the deal, and a 52% boost over its most recent daily trading.
“We are pleased to have reached this agreement with Karl Storz, which we believe maximizes value for our stockholders,” Asensus President and CEO Anthony Fernando said in a statement, with its closing expected to come in the third quarter of this year.
“This transaction is...
Today's Sponsors
Today's Sponsor